Ross D Hannan

List of Publications by Year in Descending Order

107	7,253	49	83
papers	citations	h-index	g-index
112	8,258	8.4	5.53
ext. papers	ext. citations	avg, IF	L-index

#	Paper	IF	Citations
107	The RNA polymerase I transcription inhibitor CX-5461 cooperates with topoisomerase 1 inhibition by enhancing the DNA damage response in homologous recombination-proficient high-grade serous ovarian cancer. *British Journal of Cancer*, **2021**, 124, 616-627	8.7	13
106	CX-5461 Sensitizes DNA Damage Repair-proficient Castrate-resistant Prostate Cancer to PARP Inhibition. *Molecular Cancer Therapeutics*, **2021**, 20, 2140-2150	6.1	1
105	CX-5461 activates the DNA damage response and demonstrates therapeutic efficacy in high-grade serous ovarian cancer. *Nature Communications*, **2020**, 11, 2641	17.4	45
104	Suppression of ABCE1-Mediated mRNA Translation Limits N-MYC-Driven Cancer Progression. *Cancer Research*, **2020**, 80, 3706-3718	10.1	3
103	rDNA Chromatin Activity Status as a Biomarker of Sensitivity to the RNA Polymerase I Transcription Inhibitor CX-5461. *Frontiers in Cell and Developmental Biology*, **2020**, 8, 568	5.7	9
102	A functional genetic screen defines the AKT-induced senescence signaling network. *Cell Death and Differentiation*, **2020**, 27, 725-741	12.7	13
101	Migration of Small Ribosomal Subunits on the 5'Untranslated Regions of Capped Messenger RNA. *International Journal of Molecular Sciences*, **2019**, 20,	6.3	9
100	A novel small molecule that kills a subset of MLL-rearranged leukemia cells by inducing mitochondrial dysfunction. *Oncogene*, **2019**, 38, 3824-3842	9.2	12
99	First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study. *Cancer Discovery*, **2019**, 9, 1036-1049	24.4	62
98	The long noncoding RNA lncNB1 promotes tumorigenesis by interacting with ribosomal protein RPL35. *Nature Communications*, **2019**, 10, 5026	17.4	40
97	Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 4737-4742	11.5	49
96	Palbociclib synergizes with BRAF and MEK inhibitors in treatment na�e melanoma but not after the development of BRAF inhibitor resistance. *International Journal of Cancer*, **2018**, 142, 2139-2152	7.5	41
95	Cell cycle and growth stimuli regulate different steps of RNA polymerase I transcription. *Gene*, **2017**, 612, 36-48	3.8	11
94	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. *Blood*, **2017**, 129, 2882-2895	2.2	49
93	Self-reverting mutations partially correct the blood phenotype in a Diamond Blackfan anemia patient. *Haematologica*, **2017**, 102, e506-e509	6.6	17
92	Selective inhibition of RNA polymerase I transcription as a potential approach to treat African trypanosomiasis. *PLoS Neglected Tropical Diseases*, **2017**, 11, e0005432	4.8	23
91	Inhibition of Pol I Transcription a New Chance in the Fight Against Cancer. *Technology in Cancer Research and Treatment*, **2017**, 16, 736-739	2.7	2

90	Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. *Cancer Discovery*, **2016**, 6, 59-70	24.4	73
89	Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling. *Oncotarget*, **2016**, 7, 49800-49818	3.3	62
88	Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies. *Oncotarget*, **2016**, 7, 66569-66585	3.3	17
87	Amino acid-dependent signaling via S6K1 and MYC is essential for regulation of rDNA transcription. *Oncotarget*, **2016**, 7, 48887-48904	3.3	7
86	Defining the essential function of FBP/KSRP proteins: Drosophila Psi interacts with the mediator complex to modulate MYC transcription and tissue growth. *Nucleic Acids Research*, **2016**, 44, 7646-58	20.1	13
85	Combining High-Content Imaging and Phenotypic Classification Analysis of Senescence-Associated Beta-Galactosidase Staining to Identify Regulators of Oncogene-Induced Senescence. *Assay and Drug Development Technologies*, **2016**, 14, 416-28	2.1	5
84	The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer. *Clinical Cancer Research*, **2016**, 22, 5539-5552	12.9	48
83	PR55□containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity. *Oncogene*, **2015**, 34, 1333-9	9.2	18
82	Defective Hfp-dependent transcriptional repression of dMYC is fundamental to tissue overgrowth in Drosophila XPB models. *Nature Communications*, **2015**, 6, 7404	17.4	10
81	Glucocorticoids improve erythroid progenitor maintenance and dampen Trp53 response in a mouse model of Diamond-Blackfan anaemia. *British Journal of Haematology*, **2015**, 171, 517-29	4.5	14
80	S6 Kinase is essential for MYC-dependent rDNA transcription in Drosophila. *Cellular Signalling*, **2015** , 27, 2045-53	4.9	15
79	Regulation of rDNA transcription in response to growth factors, nutrients and energy. *Gene*, **2015**, 556, 27-34	3.8	65
78	A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes. *Genome Research*, **2015**, 25, 201-12	9.7	31
77	The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2015**, 1849, 821-9	6	90
76	Genome wide mapping of UBF binding-sites in mouse and human cell lines. *Genomics Data*, **2015**, 3, 103-5		6
75	Implications of epithelial-mesenchymal plasticity for heterogeneity in colorectal cancer. *Frontiers in Oncology*, **2015**, 5, 13	5.3	20
74	Targeting RNA polymerase I to treat MYC-driven cancer. *Oncogene*, **2015**, 34, 403-12	9.2	56
73	Targeting the nucleolus for cancer intervention. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2014**, 1842, 802-16	6.9	159

72	Perturbations at the ribosomal genes loci are at the centre of cellular dysfunction and human disease. *Cell and Bioscience*, **2014**, 4, 43	9.8	36
71	Conditional inactivation of Upstream Binding Factor reveals its epigenetic functions and the existence of a somatic nucleolar precursor body. *PLoS Genetics*, **2014**, 10, e1004505	6	47
70	Targeting the nucleolus for cancer-specific activation of p53. *Drug Discovery Today*, **2014**, 19, 259-65	8.8	34
69	Widespread FRA1-dependent control of mesenchymal transdifferentiation programs in colorectal cancer cells. *PLoS ONE*, **2014**, 9, e88950	3.7	53
68	Dysregulation of RNA polymerase I transcription during disease. *Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms*, **2013**, 1829, 342-60	6	89
67	Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors. *European Journal of Cancer*, **2013**, 49, 3936-44	7.5	63
66	A functional siRNA screen identifies genes modulating angiotensin II-mediated EGFR transactivation. *Journal of Cell Science*, **2013**, 126, 5377-90	5.3	27
65	The nucleolus: an emerging target for cancer therapy. *Trends in Molecular Medicine*, **2013**, 19, 643-54	11.5	158
64	AKT signalling is required for ribosomal RNA synthesis and progression of E□Myc B-cell lymphoma in vivo. *FEBS Journal*, **2013**, 280, 5307-16	5.7	16
63	The mTORC1 inhibitor everolimus prevents and treats E□Myc lymphoma by restoring oncogene-induced senescence. *Cancer Discovery*, **2013**, 3, 82-95	24.4	52
62	Unravelling the molecular complexity of GPCR-mediated EGFR transactivation using functional genomics approaches. *FEBS Journal*, **2013**, 280, 5258-68	5.7	43
61	Dysregulation of the basal RNA polymerase transcription apparatus in cancer. *Nature Reviews Cancer*, **2013**, 13, 299-314	31.3	147
60	A novel mouse model of atherosclerotic plaque instability for drug testing and mechanistic/therapeutic discoveries using gene and microRNA expression profiling. *Circulation Research*, **2013**, 113, 252-65	15.7	124
59	Autophagy induction is a Tor- and Tp53-independent cell survival response in a zebrafish model of disrupted ribosome biogenesis. *PLoS Genetics*, **2013**, 9, e1003279	6	55
58	Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. *Blood*, **2013**, 121, 2964-74	2.2	54
57	AKT-independent PI3-K signaling in cancer - emerging role for SGK3. *Cancer Management and Research*, **2013**, 5, 281-92	3.6	60
56	Expression, regulation and putative nutrient-sensing function of taste GPCRs in the heart. *PLoS ONE*, **2013**, 8, e64579	3.7	92
55	A 19S proteasomal subunit cooperates with an ERK MAPK-regulated degron to regulate accumulation of Fra-1 in tumour cells. *Oncogene*, **2012**, 31, 1817-24	9.2	15

54	Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. *Cancer Cell*, **2012**, 22, 51-65	24.3	368
53	AKT induces senescence in human cells via mTORC1 and p53 in the absence of DNA damage: implications for targeting mTOR during malignancy. *Oncogene*, **2012**, 31, 1949-62	9.2	163
52	A phospho-proteomic screen identifies novel S6K1 and mTORC1 substrates revealing additional complexity in the signaling network regulating cell growth. *Cellular Signalling*, **2011**, 23, 1338-47	4.9	15
51	Signaling to the ribosome in cancer--It is more than just mTORC1. *IUBMB Life*, **2011**, 63, 79-85	4.7	34
50	c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation. *Nucleic Acids Research*, **2011**, 39, 3267-81	20.1	76
49	Relative Expression Levels Rather Than Specific Activity Plays the Major Role in Determining In Vivo AKT Isoform Substrate Specificity. *Enzyme Research*, **2011**, 2011, 720985	2.4	16
48	AKT promotes rRNA synthesis and cooperates with c-MYC to stimulate ribosome biogenesis in cancer. *Science Signaling*, **2011**, 4, ra56	8.8	104
47	Hfp, the Drosophila homolog of the mammalian c-myc transcriptional-repressor and tumor suppressor FIR, inhibits dmyc transcription and cell growth. *Fly*, **2011**, 5, 129-33	1.3	3
46	Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. *Cancer Research*, **2011**, 71, 1418-30	10.1	353
45	Drosophila ribosomal protein mutants control tissue growth non-autonomously via effects on the prothoracic gland and ecdysone. *PLoS Genetics*, **2011**, 7, e1002408	6	26
44	Determination of the exact molecular requirements for type 1 angiotensin receptor epidermal growth factor receptor transactivation and cardiomyocyte hypertrophy. *Hypertension*, **2011**, 57, 973-80	8.5	24
43	The renin-angiotensin system and cancer: old dog, new tricks. *Nature Reviews Cancer*, **2010**, 10, 745-59	31.3	341
42	ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells. *Genome Research*, **2010**, 20, 351-60	9.7	283
41	Hfp inhibits Drosophila myc transcription and cell growth in a TFIIH/Hay-dependent manner. *Development (Cambridge)*, **2010**, 137, 2875-84	6.6	25
40	Second AKT: the rise of SGK in cancer signalling. *Growth Factors*, **2010**, 28, 394-408	1.6	102
39	The role of UBF in regulating the structure and dynamics of transcriptionally active rDNA chromatin. *Epigenetics*, **2009**, 4, 374-82	5.7	85
38	Adenovirus-mediated delivery of relaxin reverses cardiac fibrosis. *Molecular and Cellular Endocrinology*, **2008**, 280, 30-8	4.4	40
37	UBF levels determine the number of active ribosomal RNA genes in mammals. *Journal of Cell Biology*, **2008**, 183, 1259-74	7.3	146

36	Translational control of c-MYC by rapamycin promotes terminal myeloid differentiation. *Blood*, **2008**, 112, 2305-17	2.2	78
35	Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. *Growth Factors*, **2007**, 25, 209-26	1.6	176
34	Centromere RNA is a key component for the assembly of nucleoproteins at the nucleolus and centromere. *Genome Research*, **2007**, 17, 1146-60	9.7	209
33	Cross talk between corticosteroids and alpha-adrenergic signalling augments cardiomyocyte hypertrophy: a possible role for SGK1. *Cardiovascular Research*, **2006**, 70, 555-65	9.9	50
32	A specific role for AKT3 in the genesis of ovarian cancer through modulation of G(2)-M phase transition. *Cancer Research*, **2006**, 66, 11718-25	10.1	75
31	Expression of constitutively active angiotensin receptors in the rostral ventrolateral medulla increases blood pressure. *Hypertension*, **2006**, 47, 1054-61	8.5	57
30	Effect of dominant-negative epidermal growth factor receptors on cardiomyocyte hypertrophy. *Journal of Receptor and Signal Transduction Research*, **2006**, 26, 659-77	2.6	13
29	Tackling the EGFR in pathological tissue remodelling. *Pulmonary Pharmacology and Therapeutics*, **2006**, 19, 74-8	3.5	24
28	Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. *Molecular Endocrinology*, **2004**, 18, 2344-54		83
27	Proliferation of neointimal smooth muscle cells after arterial injury. Dependence on interactions between fibroblast growth factor receptor-2 and fibroblast growth factor-9. *Journal of Biological Chemistry*, **2004**, 279, 42221-9	5.4	34
26	MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation. *EMBO Journal*, **2004**, 23, 3325-35	13	153
25	Hijacking epidermal growth factor receptors by angiotensin II: new possibilities for understanding and treating cardiac hypertrophy. *Cellular and Molecular Life Sciences*, **2004**, 61, 2695-703	10.3	34
24	Urotensin II: the old kid in town. *Trends in Endocrinology and Metabolism*, **2004**, 15, 175-82	8.8	59
23	Cardiovascular role of urotensin II: effect of chronic infusion in the rat. *Peptides*, **2004**, 25, 1783-8	3.8	34
22	Emerging Role of the Urotensin II System in Cardiovascular Disease. *Cardiology*, **2003**, 3, 153-158		2
21	AngiotensinII mediates cardiomyocyte hypertrophic growth pathways via MMP-dependent HB-EGF liberation. *International Journal of Peptide Research and Therapeutics*, **2003**, 10, 431-435		1
20	Cardiac hypertrophy: a matter of translation. *Clinical and Experimental Pharmacology and Physiology* , **2003**, 30, 517-27	3	116
19	mTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF. *Molecular and Cellular Biology*, **2003**, 23, 8862-77	4.8	349

18	Cardiac hypertrophy in vivo is associated with increased expression of the ribosomal gene transcription factor UBF. *FEBS Letters*, **2003**, 548, 79-84	3.8	12
17	Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. *Circulation Research*, **2003**, 93, 246-53	15.7	184
16	Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. *Circulation Research*, **2002** , 90, 135-42	15.7	151
15	Inositol polyphosphate 1-phosphatase is a novel antihypertrophic factor. *Journal of Biological Chemistry*, **2002**, 277, 22734-42	5.4	28
14	Combined angiotensin and endothelin receptor blockade attenuates adverse cardiac remodeling post-myocardial infarction in the rat: possible role of transforming growth factor beta(1). *Journal of Molecular and Cellular Cardiology*, **2001**, 33, 969-81	5.8	33
13	An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF. *Molecular Cell*, **2001**, 8, 1063-73	17.6	194
12	RNA polymerase I transcription in confluent cells: Rb downregulates rDNA transcription during confluence-induced cell cycle arrest. *Oncogene*, **2000**, 19, 3487-97	9.2	73
11	Rb and p130 regulate RNA polymerase I transcription: Rb disrupts the interaction between UBF and SL-1. *Oncogene*, **2000**, 19, 4988-99	9.2	114
10	Identification of a mammalian RNA polymerase I holoenzyme containing components of the DNA repair/replication system. *Nucleic Acids Research*, **1999**, 27, 3720-7	20.1	58
9	Cellular regulation of ribosomal DNA transcription:both rat and Xenopus UBF1 stimulate rDNA transcription in 3T3 fibroblasts. *Nucleic Acids Research*, **1999**, 27, 1205-13	20.1	24
8	Affinity purification of mammalian RNA polymerase I. Identification of an associated kinase. *Journal of Biological Chemistry*, **1998**, 273, 1257-67	5.4	60
7	Overexpression of the transcription factor UBF1 is sufficient to increase ribosomal DNA transcription in neonatal cardiomyocytes: implications for cardiac hypertrophy. *Proceedings of the National Academy of Sciences of the United States of America*, **1996**, 93, 8750-5	11.5	66
6	Regulation of ribosomal DNA transcription during contraction-induced hypertrophy of neonatal cardiomyocytes. *Journal of Biological Chemistry*, **1996**, 271, 3213-20	5.4	56
5	The RNA polymerase I transcription factor UBF is the product of a primary response gene. *Journal of Biological Chemistry*, **1995**, 270, 4209-12	5.4	27
4	Regulation of rDNA transcription factors during cardiomyocyte hypertrophy induced by adrenergic agents. *Journal of Biological Chemistry*, **1995**, 270, 8290-7	5.4	42
3	Expression of c-fos and related genes in the rat heart in response to norepinephrine. *Journal of Molecular and Cellular Cardiology*, **1993**, 25, 1137-48	5.8	28
2	Adrenergic agents, but not triiodo-L-thyronine induce c-fos and c-myc expression in the rat heart. *Basic Research in Cardiology*, **1991**, 86, 154-64	11.8	27
1	Targeting RNA Polymerase I transcription synergises with TOP1 inhibition in potentiating the DNA damage response in high-grade serous ovarian cancer		2